Shares of Nurix Therapeutics jumped on Wednesday after the biotech company reported stronger-than-expected results for the ...

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot ...

Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 ...

Transplants can be life-saving – but for many, the journey doesn’t end there. Up to 40% of people receiving a stem cell or bone marrow transplant will go on to develop a serious complication known as ...

UCB and Sanofi have unveiled a scientific and strategic collaboration to discover and develop novel treatments for immune-mediated diseases in areas such as gastroenterology and arthritis. The key ...

Sanofi SAN-0.11 % decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.06 % increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest ...